Primary Endpoints for Irritable Bowel Syndrome Trials: A Review of Performance of Endpoints
- 31 May 2007
- journal article
- review article
- Published by Elsevier BV in Clinical Gastroenterology and Hepatology
- Vol. 5 (5), 534-540
- https://doi.org/10.1016/j.cgh.2007.03.004
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Measuring Successful Treatment of Irritable Bowel Syndrome: Is "Satisfactory Relief " Enough?The American Journal of Gastroenterology, 2006
- Design of Treatment Trials for Functional Gastrointestinal DisordersGastroenterology, 2006
- Personal view: adequate relief as a primary endpoint in irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2006
- Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipationAlimentary Pharmacology & Therapeutics, 2004
- A double?blind, placebo?controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndromeScandinavian Journal of Gastroenterology, 2004
- Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trialThe Lancet, 2000
- Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonistAlimentary Pharmacology & Therapeutics, 1999
- A double‐blind, placebo‐controlled study of the efficacy and safety of non‐prescription ranitidine 75 mg in the prevention of meal‐induced heartburnAlimentary Pharmacology & Therapeutics, 1999
- A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scalesPain, 1994
- Measurement of pain: Patient preference does not confound pain measurementPain, 1981